Department of Medical Imaging, The University of Arizona Medical Center, Tucson, AZ, USA.
Clin Nucl Med. 2013 Sep;38(9):746-8. doi: 10.1097/RLU.0b013e3182996138.
Intense FDG uptake by bone marrow following recent chemotherapy limits evaluation for osseous metastases. The impact of marrow rebound on accuracy of (18)F-fluoride PET/CT is unclear. A 73-year-old woman with breast cancer presented for restaging FDG PET/CT, which showed intense activity throughout almost the entire axial skeleton and no osseous metastases. An (18)F-fluoride PET/CT performed 7 days later identified multiple osseous metastases in the spine, ribs, and pelvis. This case demonstrates that (18)F-fluoride PET/CT should be considered for the evaluation of osseous metastases in patients with rebound marrow uptake on FDG PET/CT.
近期化疗后骨髓摄取 FDG 增加会限制对骨转移的评估。骨髓反跳对（18）F-氟代脱氧葡萄糖 PET/CT 准确性的影响尚不清楚。一位 73 岁女性，患有乳腺癌，进行 FDG PET/CT 进行再分期，结果显示几乎整个轴向骨骼均有强烈的活性，没有骨转移。7 天后进行（18）F-氟代脱氧葡萄糖 PET/CT，发现脊柱、肋骨和骨盆多处骨转移。该病例表明，对于 FDG PET/CT 骨髓摄取增加的患者，应考虑进行（18）F-氟代脱氧葡萄糖 PET/CT 评估骨转移。
